tetano
Editor, Senior Moderator
J Infect Dis. 2017 Sep 15;216(suppl_4):S575-S580. doi: 10.1093/infdis/jix065.
[h=1]Commentary: A Historical Review of Centers for Disease Control and Prevention Antiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe Human Disease.[/h] Havers FP[SUP]1[/SUP], Campbell AP[SUP]1[/SUP], Uyeki TM[SUP]1[/SUP], Fry AM[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Human infections with novel influenza A viruses are of global public health concern, and antiviral medications have a potentially important role in treatment and prevention of human illness. Initial guidance was developed by the U.S. Centers for Disease Control and Prevention after the emergence of human infections with avian influenza A(H5N1) and has evolved over time, with identification of influenza A(H7N9) virus infections in humans, as well as detection of avian influenza viruses in birds in the United States. This commentary describes the historical context and current guidance for the use of influenza antiviral medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenza A viruses associated with severe human illness, or with the potential to cause severe human disease, and provides the scientific rationale behind current recommendations.
Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
[h=4]KEYWORDS:[/h] antiviral treatment; avian influenza; neuraminidase inhibitors
PMID: 28934460 DOI: 10.1093/infdis/jix065
[h=1]Commentary: A Historical Review of Centers for Disease Control and Prevention Antiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe Human Disease.[/h] Havers FP[SUP]1[/SUP], Campbell AP[SUP]1[/SUP], Uyeki TM[SUP]1[/SUP], Fry AM[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Human infections with novel influenza A viruses are of global public health concern, and antiviral medications have a potentially important role in treatment and prevention of human illness. Initial guidance was developed by the U.S. Centers for Disease Control and Prevention after the emergence of human infections with avian influenza A(H5N1) and has evolved over time, with identification of influenza A(H7N9) virus infections in humans, as well as detection of avian influenza viruses in birds in the United States. This commentary describes the historical context and current guidance for the use of influenza antiviral medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenza A viruses associated with severe human illness, or with the potential to cause severe human disease, and provides the scientific rationale behind current recommendations.
Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
[h=4]KEYWORDS:[/h] antiviral treatment; avian influenza; neuraminidase inhibitors
PMID: 28934460 DOI: 10.1093/infdis/jix065